From CNBC:

Pfizer’s RSV vaccine maintains protection for older adults across two seasons, showing efficacy decline but durable protection. The single dose was 77.8% effective against severe lower respiratory illness with three or more symptoms through season two. No new adverse events reported. Analysts await CDC advisory panel decision on annual or biennial shots, which could impact Moderna’s RSV jab launch. GSK’s shot in older adults showed 67.2% cumulative efficacy against lower respiratory illness over two seasons, with £1.2 billion in sales last year. Pfizer’s vaccine made about $890 million in revenue and is approved for expectant mothers. RSV causes 6,000 to 10,000 deaths and 60,000 to 160,000 hospitalizations in older adults annually.



Read more at CNBC: Pfizer RSV vaccine protects older adults over two seasons